Cypress Capital Management LLC WY maintained its stake in Merck & Company, Inc. (NYSE:MRK) during the second quarter, Holdings Channel reports. The firm owned 21,235 shares of the company’s stock at the end of the second quarter. Merck & comprises 1.6% of Cypress Capital Management LLC WY’s holdings, making the stock its 14th largest position. Cypress Capital Management LLC WY’s holdings in Merck & were worth $1,361,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Reilly Financial Advisors LLC boosted its stake in Merck & by 6.7% in the second quarter. Reilly Financial Advisors LLC now owns 5,052 shares of the company’s stock valued at $324,000 after buying an additional 316 shares in the last quarter. Atalanta Sosnoff Capital LLC boosted its stake in Merck & by 2.9% in the second quarter. Atalanta Sosnoff Capital LLC now owns 33,605 shares of the company’s stock valued at $2,154,000 after buying an additional 953 shares in the last quarter. BTIM Corp. boosted its stake in Merck & by 8.6% in the second quarter. BTIM Corp. now owns 646,655 shares of the company’s stock valued at $41,444,000 after buying an additional 50,965 shares in the last quarter. Kessler Investment Group LLC acquired a new stake in Merck & during the second quarter valued at approximately $2,193,000. Finally, Bedrijfstakpensioenfonds Voor DE Media PNO boosted its stake in Merck & by 2.2% in the second quarter. Bedrijfstakpensioenfonds Voor DE Media PNO now owns 353,191 shares of the company’s stock valued at $22,636,000 after buying an additional 7,591 shares in the last quarter. 73.73% of the stock is owned by institutional investors and hedge funds.

Merck & Company, Inc. (NYSE MRK) traded up 0.5552% during trading on Friday, reaching $62.5252. The company’s stock had a trading volume of 3,167,538 shares. Merck & Company, Inc. has a 52 week low of $58.29 and a 52 week high of $66.80. The firm has a market capitalization of $170.53 billion, a P/E ratio of 33.8523 and a beta of 0.80. The firm has a 50-day moving average price of $63.46 and a 200-day moving average price of $63.80.

Merck & (NYSE:MRK) last posted its quarterly earnings results on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.87 by $0.14. Merck & had a net margin of 17.14% and a return on equity of 26.02%. The business had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. During the same period in the prior year, the business posted $0.93 earnings per share. Merck &’s revenue for the quarter was up .9% compared to the same quarter last year. On average, equities analysts anticipate that Merck & Company, Inc. will post $3.87 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 6th. Stockholders of record on Friday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 3.02%. The ex-dividend date of this dividend is Thursday, September 14th. Merck &’s dividend payout ratio (DPR) is presently 76.11%.

ILLEGAL ACTIVITY NOTICE: This piece was originally published by Watch List News and is owned by of Watch List News. If you are accessing this piece on another site, it was stolen and reposted in violation of United States and international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/cypress-capital-management-llc-wy-holds-position-in-merck-company-inc-nysemrk/1474979.html.

Several research firms have recently commented on MRK. HSBC Holdings plc raised Merck & from a “reduce” rating to a “hold” rating in a report on Wednesday. BidaskClub cut Merck & from a “hold” rating to a “sell” rating in a report on Wednesday. Zacks Investment Research cut Merck & from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. UBS AG raised their price target on Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a report on Monday, July 31st. Finally, Piper Jaffray Companies set a $70.00 price target on Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $69.80.

Merck & Company Profile

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.